La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Coherus BioSciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Coherus BioSciences..

Coherus BioSciences (NASDAQ:CHRS) Azioni, Catena delle Opzioni

Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Coherus BioSciences Inc

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $8 to $4.

News

Price Target

Analyst Ratings

CHRS

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $4

WIIM

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.12) by 91.67 percent. The company reported quarterly sales of $70.77 million which beat the analyst consensus estimate of $59.23 million by 19.49 percent. This is a 5.09 percent decrease over sales of $74.57 million the same period last year.

Earnings

Earnings Beats

Reported November 6: Coherus BioSciences Q3 2024 Adj EPS $(0.01) Beats $(0.12) Estimate, Sales $70.77M Beat $59.23M Estimate

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXGN

CELU

CLOV

ENSC

HBIO

PSNL

XRAY

12 Health Care Stocks Moving In Thursday's Intraday Session

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Coherus Biosciences shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $4 to $1.5.

UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) from Buy to Neutral and lowers the price target from $4 to $1.5.

Downgrades

UBS Downgrades Coherus BioSciences to Neutral, Lowers Price Target to $1.5

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance

Coherus BioSciences Sees FY24 R&D And SG&A Expenses $250M-$265M

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.29) by 51.72 percent. The company reported quarterly sales of $65.000 million which beat the analyst consensus estimate of $61.366 million by 5.92 percent. This is a 10.70 percent increase over sales of $58.716 million the same period last year.

Coherus BioSciences Q2 2024 Adj. EPS $(0.14) Beats $(0.29) Estimate, Sales $65.000M Beat $61.366M Estimate

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $9 to $8.

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $8

Coherus BioSciences To Divest YUSIMRY In $40M Upfront All Cash Transaction

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $8 to $7.

Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and raises the price target from $11 to $12.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12

Coherus BioSciences shares are trading lower after the company reported better-than-expected Q1 financial results.

Earnings Misses

Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate

<ul>
<li>New $38.7 million term loan with a May 2029 maturity</li>
<li>$37.5 million royalty monetization financing based on future sales of LOQTORZI&nbsp;and UDENYCA</li>
</ul>

Biotech

Health Care

General

Coherus Announces Full Repayment of Pharmakon Advisors $75M Term Loan

Coherus BioSciences Q3 2024 Earnings Preview

Coherus BioSciences Non-GAAP EPS of -$0.01 beats by $0.10, revenue of $70.77M beats by $13.96M

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Coherus Biosciences ( ($CHRS) ) has released its Q3 earnings. Here is a breakdown of the information Coherus Biosciences presented to its investors...

Coherus BioSciences Reports Strong Q3 2024 Growth

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Coherus Biosciences (CHRS – Research Report), retaining the price target of $12....

Douglas Tsao Reaffirms Buy Rating on Coherus Biosciences Amid Strong Market Position and Growth Potential

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on CHRS stock, giving a Buy rating today. Michael Nedelcovych has given hi...

Coherus Biosciences: Strong Financial Performance and Strategic Cost Management Drive Buy Rating

Coherus stock rallies 19% on Q3 earnings, Udenyca production update

Barclays analyst Balaji Prasad maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) today and set a price target of $7.00. The c...

Coherus Biosciences (CHRS) Receives a Buy from Barclays

Truist Financial analyst Jailendra Singh maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) today. The company's shares closed...

Coherus Biosciences (CHRS) Receives a Buy from Truist Financial

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

ACRS

AKTX

AMGN

APLS

APVO

HOTH

INCY

TNXP

XCUR

Financing

Press Releases

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Management

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Comments

Coherus BioSciences

Coherus BioSciences (CHRS) Opzioni

Coherus BioSciences (NASDAQ:CHRS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO